Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Back to dashboard
Company Information
About this company
Key people
Keith R. Leonard
Independent Chairman of the Board
Neha Krishnamohan
Independent Director
Todd Franklin Watanabe
President, Chief Executive Officer and Director
Latha Vairavan
Senior Vice President and Chief Financial Officer
Masaru Matsuda
Executive Vice President, Chief Legal Officer and Corporate Secretary
Patrick E. Burnett
Executive Vice President and Chief Medical Officer
Robert Lisicki
Interim Executive Vice President, Interim Chief Commercial Officer
Terrie J. Curran
Independent Director
Halley E. Gilbert
Independent Director
Patrick J. Heron
Independent Director
Click to see more
Key facts
- Shares in issue125.69m
- EPICARQT
- ISINUS03969K1088
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.62bn
- Employees354
- ExchangeNASDAQ
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.